ABILIFY (aripiprazole) Injection
Bristol-Myers Squibb Co (Princeton, NJ) and Otsuka Pharmaceutical Co (Tokyo, Japan) recently launched ABILIFY Injection for intramuscular use. The product provides raid control of agitation in adults with schizophrenia or bipolar mania at the primary end point (2 hours). ABILIFY Injection is available in single-dose ready-to-use vials as a 9.75-mg/1.3-mL (7.5-mg/mL), clear, colorless, sterile, aqueous solution. The recommended dose is 9.75 mg. For more information, visit www.abilify.com.
Hycamtin (topotecan HCl) Injection
GlaxoSmithKline's (Research Triangle Park, NC) Hycamtin Injection has a new indication. The product, in combination with cisplatin, is indicated for the treatment of histologically confirmed stage IV-B, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Hycamtin Injection is also indicated for the treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy, and the treatment of small cell lung cancer sensitive disease after failure of firstline chemotherapy. Prior to the administration of the first course of Hycamtin Injection for patients with cervical cancer, patients must have a baseline absolute neutrophil count of >1500 cells/mm3 and a platelet count of >100,000 cells/mm3. The recommended dose of the product is 0.75 mg/m2 by intravenous (IV) infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by IV infusion on day 1 repeated every 21 days (a 21-day course). Prior to the administration of the first course of Hycamtin Injection for patients with ovarian/small cell lung cancer, patients must have a baseline neutrophil count of >1500 cells/mm3 and a platelet count of >100,000 cells/mm3. The recommended dose of Hycamtin Injection is 1.5 mg/m2 by IV infusion over 30 minutes daily for 5 consecutive days, starting on day 1 of a 21-day course. For more information, visit www.hycamtin.com.
INVANZ (ertapenem for injection)
Merck & Co Inc (Whitehouse Station, NJ) recently received FDA approval for INVANZ for the prophylaxis of surgical site infection following elective colorectal surgery in adults. In addition to the new indication, the product is indicated for the treatment of adults and pediatric patients >3 months of age for the following moderate-to-severe infections caused by susceptible isolates of the designated pathogens: complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, complicated urinary tract infections, and acute pelvic infections. The dose of INVANZ in patients aged 13 years and older is 1 g given once a day. The INVANZ dose in patients aged 3 months to 12 years is 15 mg/kg twice a day. The product may be administered by intravenous infusion for up to 14 days or intramuscular injection for up to 7 days. When administered intravenously, INVANZ should be infused over a 30-minute period. For more information, visit www.invanz.com.
Ondansetron Injection USP
Abraxis Pharmaceutical Products (Schaumburg, Ill) recently launched Ondansetron Injection USP. The product is bar-coded, latex-free, AP-rated, and the generic equivalent of Zofran Injection (GlaxoSmithKline). The product is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and prevention of postoperative nausea and/or vomiting. Ondansetron Injection USP is available in single-dose and multiple-dose vials. For more information, visit www.appdrugs.com, or call 800-551-7176.
EPS Inc (Ivyland, Pa) has expanded its line of safety products for use in the preparation and dispensing of medication. SafeBreak disposable plastic fracture and safety collars were designed to protect practitioners from glass splinters when breaking ampules. The SafeBreak collar is available in 3 sizes to accommodate all sizes of ampules. The product works by fitting the collar over the top of the ampule, squeezing tightly, and snapping safely to open. For more information, call 800-523-8966, or visit www.medi-dose.com.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs